About Biltmore Medical Associates
Clinical Trials at Biltmore Medical Associates
During the past decade, Biltmore Medical Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Biltmore Medical Associates
According to Clinical.Site data, the most researched conditions in "Biltmore Medical Associates" are
"Osteoarthritis" (2 trials). Many other conditions were trialed in "Biltmore Medical Associates" in a lesser frequency.
Clinical Trials Intervention Types at Biltmore Medical Associates
Most popular intervention types in "Biltmore Medical Associates" are "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (2 trials), "Tanezumab" (1 trials) and "tanezumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Biltmore Medical Associates
The vast majority of trials in "Biltmore Medical Associates" are
2 trials for "All" genders.
Clinical Trials Status at Biltmore Medical Associates
Currently, there are NaN active trials in "Biltmore Medical Associates".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Biltmore Medical Associates,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Biltmore Medical Associates, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".